CDC’s Investments to Combat Antibiotic Resistance Threats Nationwide : Mississippi
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
Clear All

CDC’s Investments to Combat Antibiotic Resistance Threats Nationwide : Mississippi

Filetype[PDF-316.10 KB]

  • Description:
    $396,023 Funding for AR Activities Fiscal Year 2017 Funding to local health departments: $133,224 - RAPID DETECTION & RESPONSE to emerging drug-resistant germs is critical to contain the spread of these infections. With 2016 funding, Mississippi increased its ability to respond to emerging threats by implementing and validating new testing methods for HAI/AR detection. The Mississippi Public Health Lab performed phenotypic and genotypic $133,224 characterization on 89 “nightmare bacteria” CRE and CRPA isolates. $94,635 - FOOD SAFETY projects protect communities by rapidly identifying drug-resistant foodborne bacteria to stop and solve outbreaks and improve prevention. In Fiscal Year 2018, Mississippi will ramp up testing to include whole genome sequencing of all Listeria, Salmonella, Campylobacter and E. coli isolates and simultaneously monitor these isolates for resistance genes. States upload the sequence data into PulseNet for nationwide monitoring of outbreaks and trends. When outbreaks are detected, local CDC-supported epidemiologists investigate the cases to stop spread. Funding to Universities and healthcare partners: $168,164 - UNIVERSITY OF MISSISSIPPI MEDICAL CENTER: Innovative Prevention & Tracking. Investigators will compare genome analysis methods that determine the source of genetic material. This project will help researchers to understand the relationships and transmission of antibiotic-resistant bacteria. Publication date from document properties. Mississippi-2017-CDC-AR-Investments.pdf
  • Place as Subject:
  • Main Document Checksum:
  • File Type:
  • Supporting Files:
    No Additional Files

You May Also Like: